Form D · Biotechnology
Altay Therapeutics, Inc.
San Carlos, CA · CIK 0002157551
Offering snapshot reported Oct 2, 2026 · SEC filing
- Reported sold
- $15.7M Offering amount: $45.1M
- Investors reported
- 19 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 17, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 2, 2026 | Initial | $15,738,155 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-599839
Source: Form D, filed Oct 2, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric Bjerkholt | Director |
| James Breitmeyer | Director, Executive |
| Mike Grey | Director |
| Chelsea Johnson | Director |
| Aidan King | Director |
| Ali Ozes | Executive |
| Ester Sklarsky | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
733 Industrial Road
San Carlos, CA, 94070
Phone: (650) 455-1147
San Carlos, CA, 94070
Phone: (650) 455-1147